Transforming growth factor beta (TGF-beta) acts as a potent inhibitor of the growth and functions of lymphoid and hemopoietic progenitor cells. Cell proliferation depends not only on the presence of growth factors, but also on the development of specific receptor-signal transducing complexes. We therefore investigated whether the inhibitory actions of TGF-beta could be mediated by inhibition of growth factor receptors. TGF-beta inhibited the constitutive level of interleukin 1 receptor (IL-1R) expression on several murine lymphoid and myeloid progenitor cell lines, as well as IL-1R expression induced by interleukin 3 (IL-3) on normal murine and human bone marrow cells. Furthermore, treatment of bone marrow progenitor cells with TGF-beta concomitantly inhibited the ability of IL-1 to promote high proliferative potential (HPP) colony formation as well as blocked IL-1-induced IL-2 production by EL-4 6.1 cells. These findings provide the first evidence that the inhibitory action of TGF-beta on the growth and functional activities of hematopoietic and T cells is associated with a reduction in the cell surface receptor expression for IL-1.
Skip Nav Destination
Article navigation
1 September 1990
Article|
September 01 1990
Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action.
C M Dubois,
C M Dubois
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
Search for other works by this author on:
F W Ruscetti,
F W Ruscetti
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
Search for other works by this author on:
E W Palaszynski,
E W Palaszynski
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
Search for other works by this author on:
L A Falk,
L A Falk
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
Search for other works by this author on:
J J Oppenheim,
J J Oppenheim
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
Search for other works by this author on:
J R Keller
J R Keller
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
Search for other works by this author on:
C M Dubois
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
F W Ruscetti
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
E W Palaszynski
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
L A Falk
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
J J Oppenheim
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
J R Keller
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1990) 172 (3): 737–744.
Citation
C M Dubois, F W Ruscetti, E W Palaszynski, L A Falk, J J Oppenheim, J R Keller; Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action.. J Exp Med 1 September 1990; 172 (3): 737–744. doi: https://doi.org/10.1084/jem.172.3.737
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement